(NYSE:EQS),(OtherOTC:GEVI), HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) — Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of June 30, 2025, of $34.1 million. Net asset value per share decreased to $2.51 as of June 30, 2025, from $2.52 as of March 31, 2025. Comparative data is summarized below (in […]

(NasdaqGM:CRML), Superior drilling results continue to exceed the Company's expectations and are expanding Tanbreez at vast scale and build upon very successful past Tanbreez drilling results. Consistent uniformity across the deposits intersecting ultra high-grade rare earth element mineralisation intersected in all four reported holes, with total rare earth oxide (TREO) grades between 0.48% and 0.55%.

(NASDAQ:DFDV), BOCA RATON, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually

(NASDAQ:RARE), NOVATO, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for DTX401 AAV gene therapy as a treatment for Glycogen Storage Disease Type Ia (GSDIa). The company

(NasdaqGM:NAMS),(NasdaqGM:NAMSW), — Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia — — NewAmsterdam entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in

(CNSX:SHRC.CN),(OTC US:INTWF),(Other OTC:INTWF),(Frankfurt:IWIA),(CNSX:SHRC), VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that, further to its news release dated August 1, 2025, the Company has closed a non-brokered private placement of unsecured convertible debentures of the

(NasdaqGM:AMOD),(NASDAQ:AMODW), CHARLOTTE, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), a leader in AI-powered retail engagement technologies, today announced that it has entered into an agreement for a transformative capital restructuring that will eliminate approximately $41 million in mezzanine equity, dramatically reduce the Company's stockholders'

(NASDAQ:IRD), – Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) — Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders,

(NYSE:PTHS), Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025 Strong physician response following successful launch of ZELSUVMI(TM) (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and older Completes build-out

(NASDAQ:LIXT),(NASDAQ:LIXTW), -Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- –Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) —